Logo image of ANIX

ANIXA BIOSCIENCES INC (ANIX) Stock Price, Quote, News and Overview

NASDAQ:ANIX - Nasdaq - US03528H1095 - Common Stock - Currency: USD

2.76  +0.06 (+2.22%)

ANIX Quote, Performance and Key Statistics

ANIXA BIOSCIENCES INC

NASDAQ:ANIX (4/25/2025, 8:00:00 PM)

2.76

+0.06 (+2.22%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High4.2
52 Week Low2.07
Market Cap88.87M
Shares32.20M
Float29.87M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO10-07 1983-10-07


ANIX short term performance overview.The bars show the price performance of ANIX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -5 -10 -15

ANIX long term performance overview.The bars show the price performance of ANIX in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30

The current stock price of ANIX is 2.76 USD. In the past month the price decreased by -10.39%. In the past year, price decreased by -14.55%.

ANIXA BIOSCIENCES INC / ANIX Daily stock chart

ANIX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.12 329.14B
AMGN AMGEN INC 14.17 150.99B
GILD GILEAD SCIENCES INC 13.33 128.61B
VRTX VERTEX PHARMACEUTICALS INC 1702.9 126.96B
REGN REGENERON PHARMACEUTICALS 13.2 65.88B
ARGX ARGENX SE - ADR 323.56 37.54B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.72B
ONC BEIGENE LTD-ADR N/A 26.39B
BNTX BIONTECH SE-ADR N/A 24.52B
NTRA NATERA INC N/A 20.79B
BIIB BIOGEN INC 7.22 17.39B
SMMT SUMMIT THERAPEUTICS INC N/A 17.30B

About ANIX

Company Profile

ANIX logo image Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology and infectious disease. The company is headquartered in San Jose, California and currently employs 5 full-time employees. The firm's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The firm's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. The firm is engaged in the development of vaccines for the treatment or prevention of triple negative breast cancer and other breast cancers which express the α-lactalbumin protein. Its vaccine technologies are focused on immunizing against retired proteins that have been found to be expressed in certain forms of cancer.

Company Info

ANIXA BIOSCIENCES INC

3150 Almaden Expy Ste 250

San Jose CALIFORNIA 95118 US

CEO: Amit Kumar

Employees: 5

Company Website: https://www.anixa.com/

Investor Relations: http://www.ir.anixa.com

Phone: 14087089808

ANIXA BIOSCIENCES INC / ANIX FAQ

What is the stock price of ANIXA BIOSCIENCES INC today?

The current stock price of ANIX is 2.76 USD. The price increased by 2.22% in the last trading session.


What is the ticker symbol for ANIXA BIOSCIENCES INC stock?

The exchange symbol of ANIXA BIOSCIENCES INC is ANIX and it is listed on the Nasdaq exchange.


On which exchange is ANIX stock listed?

ANIX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ANIXA BIOSCIENCES INC stock?

9 analysts have analysed ANIX and the average price target is 9.18 USD. This implies a price increase of 232.61% is expected in the next year compared to the current price of 2.76. Check the ANIXA BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ANIXA BIOSCIENCES INC worth?

ANIXA BIOSCIENCES INC (ANIX) has a market capitalization of 88.87M USD. This makes ANIX a Micro Cap stock.


How many employees does ANIXA BIOSCIENCES INC have?

ANIXA BIOSCIENCES INC (ANIX) currently has 5 employees.


What are the support and resistance levels for ANIXA BIOSCIENCES INC (ANIX) stock?

ANIXA BIOSCIENCES INC (ANIX) has a support level at 2.6 and a resistance level at 2.83. Check the full technical report for a detailed analysis of ANIX support and resistance levels.


Should I buy ANIXA BIOSCIENCES INC (ANIX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ANIXA BIOSCIENCES INC (ANIX) stock pay dividends?

ANIX does not pay a dividend.


What is the Price/Earnings (PE) ratio of ANIXA BIOSCIENCES INC (ANIX)?

ANIXA BIOSCIENCES INC (ANIX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.39).


What is the Short Interest ratio of ANIXA BIOSCIENCES INC (ANIX) stock?

The outstanding short interest for ANIXA BIOSCIENCES INC (ANIX) is 1.28% of its float. Check the ownership tab for more information on the ANIX short interest.


ANIX Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ANIX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ANIX. No worries on liquidiy or solvency for ANIX as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ANIX Financial Highlights

Over the last trailing twelve months ANIX reported a non-GAAP Earnings per Share(EPS) of -0.39. The EPS decreased by -14.71% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -66.03%
ROE -69.92%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%0%
Sales Q2Q%N/A
EPS 1Y (TTM)-14.71%
Revenue 1Y (TTM)-100%

ANIX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to ANIX. The Buy consensus is the average rating of analysts ratings from 9 analysts.


Ownership
Inst Owners16.41%
Ins Owners2.39%
Short Float %1.28%
Short Ratio5.27
Analysts
Analysts82.22
Price Target9.18 (232.61%)
EPS Next Y4.98%
Revenue Next YearN/A